FINWIRES · TerminalLIVE
FINWIRES

ZYUS Life Sciences Announces Strategic Realignment to Prioritize Drug Development

By

ZYUS Life Sciences (ZYUS.V) on Thursday announced a strategic realignment of its corporate structure and leadership as the clinical-stage drug developer sharpens its focus on core clinical development programs.

The company said it will discontinue its international business development activities, a move aimed at reducing overhead costs and redirecting resources toward its non-opioid pain management drug development pipeline. As part of the initiative, ZYUS will also begin a formal wind-down of its international legal entities.

In connection with the restructuring, Keith Carpenter will step down as chief strategy and investment officer, effective June 11.

"This realignment reflects our commitment to focusing resources on the areas that we believe will create the greatest value for patients and shareholders," said chief executive Brent Zettl.

The company's shares last traded May 8 on the TSX Venture Exchange, after being halted by regulators until the company provides annual audited financial statements for 2025.

Related Articles

Mining & Metals

Major Drilling Group International Posts Higher Profit, Revenue for Fiscal Fourth Quarter

Major Drilling Group International (MDI.TO) after trade Wednesday said its fiscal fourth-quarter profit and revenue rose year-over-year.The company earned $8.2 million, or $0.10 per share, in the period, up from $1 million, or $0.01, a year ago. FactSet expected $0.08 per share.Revenue rose 25% to $233.7 million from $187.5 million in the year-ago quarter. FactSet projected $228.9 million."The unfavourable foreign exchange translation impact on revenue for the quarter, when compared to the effective rates for the same period last year, was approximately $1 million, with minimal impact on net earnings as expenditures in foreign jurisdictions tend to be in the same currency as revenue," the company said, adding that revenue from Canada-U.S. drilling operations rose 66.5% to $97.9 million, and South and Central American revenue climbed 3.5% to $91.1 million year-over-year," thr company said.Looking ahead, Chief Executive Denis Larocque said, "margin expansion is expected to lag revenue growth at the beginning of fiscal 2027 as pricing catches up and outpaces initial cost increase".The company projects to incur about $75 million in capital expenditures in fiscal 2027, broadly in line with the capex guidance provided in previous years, Chief Financial Officer Ian Ross added.

$MDI.TO
Mining & Metals

Update: -- Haivision Systems Brief: Reports Q2 Revenue of $32.5 Million, a 5.1% Decrease from the Year-Prior Quarter

$HAI.TO
Mining & Metals

Haivision Systems Brief: Reports a Q2 Loss of $1.8 Million Compared to a Loss of $2.4 Million in the year-Prior Period

$HAI.TO